上海交通大学学报（医学版）

上海交通大学学报（医学版） >

2023 , Vol. 43 >Issue 12: 1585 - 1590

DOI: https://doi.org/10.3969/j.issn.1674-8115.2023.12.015

综述

非酒精性脂肪性肝病对乙型肝炎病毒感染影响的研究进展

  • BENEDICK Jun Er Chin ,
  • SON Peng ,
  • 张亦凡 ,
  • 王俊青 ,
  • 郭斯敏
展开
  • 1.上海交通大学医学院，上海 200025
    2.上海交通大学医学院附属瑞金医院肝胆外科，上海 200025
    3.上海交通大学医学院附属瑞金医院感染科，上海 200025
BENEDICK Jun Er Chin（1997—），男，马来西亚，学士；电子信箱：juner_97@icloud.com。
郭斯敏，电子信箱：gosmiling@163.com。

收稿日期: 2023-10-31

  录用日期: 2023-11-30

  网络出版日期: 2024-02-01

收起

Research progress of the impact of nonalcoholic fatty liver disease on chronic hepatitis B infection

  • Jun Er Chin BENEDICK ,
  • Peng SON ,
  • Yifan ZHANG ,
  • Junqing WANG ,
  • Simin GUO
Expand
  • 1.Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
    2.Department of Hepatobiliary Surgery, Ruijin Hospital, Shanghai Jiao Tong University Medical School, Shanghai 200025, China
    3.Infectious Department, Ruijin Hospital, Shanghai Jiao Tong University Medical School, Shanghai 200025, China
GUO Simin, E-mail: gosmiling@163.com.

Received date: 2023-10-31

  Accepted date: 2023-11-30

  Online published: 2024-02-01

Fold

摘要

慢性乙型肝炎（chronic hepatitis B，CHB）是由乙型肝炎病毒（hepatitis B virus，HBV）持续感染所致的一种传染性疾病，在世界范围内有较高的流行率。非酒精性脂肪性肝病（non-alcoholic fatty liver disease，NAFLD）是除酒精和其他肝损伤因素以外，一组与代谢异常相关的肝脏疾病。近年来，随着人们生活水平的提高和生活方式的改变，NAFLD发病率逐年升高，已成为中国以及西方国家最常见的肝脏疾病，同时也是西方国家肝移植的第二大原因。NAFLD患病率的升高导致了慢性HBV感染合并NAFLD的发病率也随之升高。但目前国内外对此2种疾病之间的关系，包括NAFLD对HBV感染者疾病演变、发病机制，以及抗病毒疗效的影响及预后争议较多，且目前国内外指南均未对其诊疗方案进行详细描述。该文归纳总结了近年来HBV感染合并NAFLD的相关研究进展，包括HBV感染合并NAFLD的流行病学、诊断标准，HBV感染合并NAFLD对乙型肝炎病毒学的影响，NAFLD对HBV负性抑制的可能机制，HBV感染合并NAFLD对抗病毒治疗效果的影响以及HBV感染者合并NAFLD的预后，以期进一步深入认识疾病本身，并为基础研究、临床研究及诊疗方案提供新思路。

关键词： 乙型肝炎病毒; 慢性乙型肝炎; 非酒精性脂肪性肝病; 抗病毒治疗; 肝癌

本文引用格式

BENEDICK Jun Er Chin , SON Peng , 张亦凡 , 王俊青 , 郭斯敏 . 非酒精性脂肪性肝病对乙型肝炎病毒感染影响的研究进展[J]. 上海交通大学学报（医学版）, 2023 , 43(12) : 1585 -1590 . DOI: 10.3969/j.issn.1674-8115.2023.12.015

Abstract

Chronic hepatitis B (CHB) is an infectious disease caused by persistent infection with the hepatitis B virus (HBV) and is highly prevalent worldwide. Non-alcoholic fatty liver disease (NAFLD) is a group of liver diseases related to metabolic abnormalities, excluding those caused by alcohol consumption or other liver injury factors. In recent years, with improvement of living standards and changes in lifestyle, the incidence of NAFLD has been increasing substantially, becoming the most common type of liver diseases in China and Western countries, and the second leading cause of liver transplantation in the West. The rising prevalence of NAFLD has also led to an increase in the incidence of NAFLD in patients with chronic HBV infection. However, there is considerable controversy both domestically and internationally regarding the relationship between these two diseases, including the disease progression, pathogenesis, impact on antiviral treatment efficacy, and prognosis of these concomitant CHB and NAFLD patients. Currently, both domestic and international guidelines lack detailed descriptions of diagnostic and treatment strategies for these conditions. This article summarizes the recent research progress in concomitant CHB and NAFLD, including epidemiology, diagnostic criteria, the impact of NAFLD on the virology of HBV infection, potential mechanisms of NAFLD-induced negative regulation of HBV, the effect of NAFLD on antiviral therapy efficacy, and prognosis. This article aims to gain a deeper understanding of the diseases themselves and provide new insights for basic and clinical research as well as diagnostic and treatment approaches.

Key words： hepatitis B virus (HBV); chronic hepatitis B (CHB); non-alcoholic fatty liver disease (NAFLD); antiviral therapy; hepatocellular carcinoma

参考文献

1 ESLAM M, SANYAL A J, GEORGE J, et al. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology, 2020, 158(7): 1999-2014.e1.
2 World Health Organization. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Accountability for the global health sector strategies 2016?2021: actions for impact. Web annex 1: key data at a glance[EB/OL]. [2023-10-30]. https://apps.who.int/iris/bitstream/handle/10665/342808/9789240030985-eng.pdf.
3 YOUNOSSI Z M, KOENIG A B, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease: meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64(1): 73-84.
4 SHI Y W, YANG R X, FAN J G. Chronic hepatitis B infection with concomitant hepatic steatosis: current evidence and opinion[J]. World J Gastroenterol, 2021, 27(26): 3971-3983.
5 ZHONG G C, WU Y L, HAO F B, et al. Current but not past hepatitis B virus infection is associated with a decreased risk of nonalcoholic fatty liver disease in the Chinese population: a case-control study with propensity score analysis[J]. J Viral Hepat, 2018, 25(7): 842-852.
6 HUANG J, JING M, WANG C, et al. The impact of hepatitis B virus infection status on the prevalence of nonalcoholic fatty liver disease: a population-based study[J]. J Med Virol, 2020, 92(8): 1191-1197.
7 BACAKSIZ F, G?KCAN H, AKDO?AN M, et al. Role of hepatosteatosis in HBsAg seroconversion in HBeAg-negative chronic hepatitis B patients[J]. Int J Clin Pract, 2021, 75(12): e14899.
8 LIU L, LI H, ZHANG Y, et al. Hepatitis B virus infection combined with nonalcoholic fatty liver disease: interaction and prognosis[J]. Heliyon, 2023, 9(1): e13113.
9 HU D, WANG H, WANG H, et al. Non-alcoholic hepatic steatosis attenuates hepatitis B virus replication in an HBV-immunocompetent mouse model[J]. Hepatol Int, 2018, 12(5): 438-446.
10 CEYLAN B, ARSLAN F, BATIREL A, et al. Impact of fatty liver on hepatitis B virus replication and virologic response to tenofovir and entecavir[J]. Turk J Gastroenterol, 2016, 27(1): 42-46.
11 郑伟, 潘宏义, 吴青青, 等. 慢性乙型肝炎合并肝脂肪变性患者的临床及病理特征分析[J]. 中华临床感染病杂志, 2019, 12(2): 87-92.
11 ZHENG W, PAN H Y, WU Q Q, et al. Analysis of clinical and pathological features of chronic hepatitis B patients with hepatic steatosis[J]. Chinese Journal of Clinical Infectious Diseases, 2019, 12(2): 87-92.
12 ZHANG J, LIN S, JIANG D, et al. Chronic hepatitis B and non-alcoholic fatty liver disease: conspirators or competitors?[J]. Liver Int, 2020, 40(3): 496-508.
13 HE W, REBELLO O, SAVINO R, et al. TLR4 triggered complex inflammation in human pancreatic islets[J]. Biochim Biophys Acta Mol Basis Dis, 2019, 1865(1): 86-97.
14 RIUS-PéREZ S, TORRES-CUEVAS I, MILLáN I, et al. PGC-1α, inflammation, and oxidative stress: an integrative view in metabolism[J]. Oxid Med Cell Longev, 2020, 2020: 1452696.
15 PICCININ E, VILLANI G, MOSCHETTA A. Metabolic aspects in NAFLD, NASH and hepatocellular carcinoma: the role of PGC1 coactivators[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(3): 160-174.
16 SHLOMAI A, PARAN N, SHAUL Y. PGC-1α controls hepatitis B virus through nutritional signals[J]. Proc Natl Acad Sci U S A, 2006, 103(43): 16003-16008.
17 HUI R W H, SETO W K, CHEUNG K S, et al. Inverse relationship between hepatic steatosis and hepatitis B viremia: results of a large case-control study[J]. J Viral Hepat, 2018, 25(1): 97-104.
18 KANDA T, MATSUOKA S, YAMAZAKI M, et al. Apoptosis and non-alcoholic fatty liver diseases[J]. World J Gastroenterol, 2018, 24(25): 2661-2672.
19 ESLAM M, VALENTI L, ROMEO S. Genetics and epigenetics of NAFLD and NASH: clinical impact[J]. J Hepatol, 2018, 68(2): 268-279.
20 ESLAM M, MANGIA A, BERG T, et al. Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes[J]. Hepatology, 2016, 64(1): 34-46.
21 KIM D S, JEON M Y, LEE H W, et al. Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir[J]. Clin Mol Hepatol, 2019, 25(3): 283-293.
22 MAK L Y, HUI R W, FUNG J, et al. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B[J]. J Hepatol, 2020, 73(4): 800-806.
23 高红伟, 毛重山, 张淑凤, 等. 恩替卡韦治疗慢性乙型肝炎合并非酒精性脂肪性肝病的效果观察[J]. 中国实用医刊, 2020, 47(22): 85-88.
23 GAO H W, MAO C S, ZHANG S F, et al. Efficacy of entecavir in the treatment of chronic hepatitis B complicated with nonalcoholic fatty liver disease[J]. Chinese Journal of Practical Medicine, 2020, 47(22): 85-88.
24 LI J, RUI F, GARCIA E, et al. Antiviral therapy response in chronic hepatitis B patients with and without fatty liver: a systematic review and meta-analysis[C/OL]. Proceedings of the 32th APASL 2023, Taipei, China, February 15?19, 2023[2023-10-30]. https://www.apasl2023.tw/#/page/ABSTRACT%20BOOK.
25 MAK L Y, SETO W K, HUI R W, et al. Fibrosis evolution in chronic hepatitis B e antigen-negative patients across a 10-year interval[J]. J Viral Hepat, 2019, 26(7): 818-827.
26 SHARIF A, ABBAS Z, AHMED S, et al. Effect of non-alcoholic fatty liver disease on transaminase levels and transient elastography in patients with chronic hepatitis B[J]. Cureus, 2019, 11(10): e5995.
27 HU D, DIAO Y, WANG H, et al. Clinical features and severity of non-obese nonalcoholic fatty liver disease in patients with chronic hepatitis B[C/OL]. Proceedings of the 32th APASL 2023, Taipei, China, February 15?19, 2023[2023-10-30]. https://www.apasl2023.tw/#/page/ABSTRACT%20BOOK.
28 CHAN A W, WONG G L, CHAN H Y, et al. Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B[J]. J Gastroenterol Hepatol, 2017, 32(3): 667-676.
29 CHO H, CHANG Y, LEE J H, et al. Radiologic nonalcoholic fatty liver disease increases the risk of hepatocellular carcinoma in patients with suppressed chronic hepatitis B[J]. J Clin Gastroenterol, 2020, 54(7): 633-641.
30 PELEG N, ISSACHAR A, SNEH ARBIB O, et al. Liver steatosis is a strong predictor of mortality and cancer in chronic hepatitis B regardless of viral load[J]. JHEP Rep, 2019, 1(1): 9-16.
31 ZHANG N, WANG Y, ZHANG J, et al. N-glycosylation of CREBH improves lipid metabolism and attenuates lipotoxicity in NAFLD by modulating PPARα and SCD-1[J]. FASEB J, 2020, 34(11): 15338-15363.
32 VINCIGUERRA M, CARROZZINO F, PEYROU M, et al. Unsaturated fatty acids promote hepatoma proliferation and progression through downregulation of the tumor suppressor PTEN[J]. J Hepatol, 2009, 50(6): 1132-1141.
33 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 中华临床感染病杂志, 2022, 15(6): 401-427.
33 Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2022)[J]. Chinese Journal of Clinical Infectious Diseases, 2022, 15(6): 401-427.
Options
文章导航

/

〈 〉